Trastuzumab News and Research

RSS

New subcutaneous treatment reduces pain, increases survival chances of breast cancer patients

Breast cancer treatments are usually painful, time consuming and aggressive, which leads to long term hospitalization, medical staff and high economic expenses.

19 Jul 2016

Penn study provides more insights into cardiovascular side effects of breast cancer drug

A receptor protein that is the target of the breast cancer drug trastuzumab (Herceptin) is needed for proper heart blood-vessel development, reported researchers from the Perelman School of Medicine at the University of Pennsylvania.

14 Jul 2016

Understanding chemotherapy cost differences could help patients in making informed decisions

Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. Understanding cost differences should help guide informed discussions between patients and physicians when considering chemotherapy options.

6 Jun 2016

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Despite the known toxic effects of chemotherapy on the heart, the majority of women undergoing breast cancer treatment are not getting the recommended follow-up heart scans, according to research presented at the British Cardiovascular Society Conference in Manchester today.

6 Jun 2016

UZH scientists identify new class of protein compounds to treat HER2-positive breast cancer

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms of breast cancer, the cells have too much of the receptor HER2 on their surface.

3 Jun 2016

First large-scale proteogenomic study helps pinpoint genes that drive breast cancer

Building on data from The Cancer Genome Atlas project, a multi-institutional team of scientists has completed the first large-scale "proteogenomic" study of breast cancer, linking DNA mutations to protein signaling and helping pinpoint the genes that drive cancer.

26 May 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

Herceptin drugs for breast cancer linked with increased risk of congestive heart failure

Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences (ICES) and the Ted Rogers Centre for Heart Research, University Health Network.

20 Apr 2016

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab.

19 Apr 2016

Study reveals low rates of targeted drug use among older black women with early-stage breast cancer

The advent of targeted drugs for a specific type of breast cancer - HER2 positive - has dramatically improved survival rates for women with the disease. But a study led by researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center reveals low rates of use of a targeted drug among older women with early-stage breast cancer of this type, and even lower rates for older black women.

13 Apr 2016

'Modest support' for PFS as OS surrogate in HER2-positive metastatic breast cancer

Progression-free survival only moderately correlates with overall survival at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with HER2-targeted agents, say researchers.

23 Mar 2016

Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer.

18 Mar 2016

Combining photoimmunotherapy and gene transduction effective against elusive gastric cancer cells

Researchers report photoimmunotherapy to be effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2. The results are published in the journal Small Molecule Therapeutics in February 2016.

15 Mar 2016

Preoperative lapatinib plus trastuzumab elicits response in HER2-positive breast cancer

Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research.

14 Mar 2016

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis.

11 Mar 2016

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.

11 Mar 2016

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according to results from a clinical trial.

11 Mar 2016

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.

26 Feb 2016

Mutation or amplification of HER2 gene may lead to lung cancer

A joint study by University of Colorado Cancer Center and Memorial Sloan Kettering Cancer Center published in the Journal of Thoracic Oncology shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene.

29 Jan 2016

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells.

26 Nov 2015

Trastuzumab News and Research

New subcutaneous treatment reduces pain, increases survival chances of breast cancer patients

Penn study provides more insights into cardiovascular side effects of breast cancer drug

Understanding chemotherapy cost differences could help patients in making informed decisions

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

UZH scientists identify new class of protein compounds to treat HER2-positive breast cancer

First large-scale proteogenomic study helps pinpoint genes that drive breast cancer

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

Herceptin drugs for breast cancer linked with increased risk of congestive heart failure

New drug combination before surgery may improve outcomes in breast cancer patients

Study reveals low rates of targeted drug use among older black women with early-stage breast cancer

'Modest support' for PFS as OS surrogate in HER2-positive metastatic breast cancer

Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of breast cancer subtypes

Combining photoimmunotherapy and gene transduction effective against elusive gastric cancer cells

Preoperative lapatinib plus trastuzumab elicits response in HER2-positive breast cancer

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Mutation or amplification of HER2 gene may lead to lung cancer

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News